This one had results with a population of heavily pretreated patients, in some cases at 4th line treatment in castrate resistant setting. They are talking about a potential SOC changes in prostate cancer for very advanced patients.
AMG 509 Xaluritamig: latest data disc... - Advanced Prostate...
AMG 509 Xaluritamig: latest data discussed by dr Sartor, very promising on heavily pretreated patients
Written by
Maxone73
To view profiles and participate in discussions please or .
6 Replies
•
Good news for us that have been heavily treated and running out of options. Having to be hospitalized for the first 24 hours could be a problem with our health care system.
Dr. Sartor is cohosting a summit today at 1pm eastern time pcf.org/patientsummits/
Registered! Thank you!
Not what you're looking for?
You may also like...
Examining Prostate Cancer Survival Outcomes by Patient Age and Treatment Type in Patients with mHSPC
“the research suggests a differential impact between androgen receptor antagonists (like...
Radiation & Oligometastatic PCa.
Interesting interview for those with low-volume disease....
New Lu177 trials in Australia
I looked through the slides of Prof. Hofman which he presented at the APCCC 2019 conference in...
Apalutamide aka Erleada = Good Stuff!
These findings were mentioned a couple of months back but they're worth repeating with a nice video...